Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free AQB Stock Alerts

AquaBounty Technologies (AQB) Competitors

AquaBounty Technologies logo
$1.27 +0.03 (+2.00%)
As of 04:00 PM Eastern
Compare

AQB vs. BCTX, GNTA, NXTC, TVGN, and KYNB

Should you buy AquaBounty Technologies stock or one of its competitors? AquaBounty Technologies's main competitors and comparable companies include Briacell Therap (BCTX), Genenta Science (GNTA), NextCure (NXTC), Tevogen Bio (TVGN), and Kyntra Bio (KYNB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AquaBounty Technologies compare to Briacell Therap?

AquaBounty Technologies (NASDAQ:AQB) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

AquaBounty Technologies' return on equity of -147.07% beat Briacell Therap's return on equity.

Company Net Margins Return on Equity Return on Assets
AquaBounty TechnologiesN/A -147.07% -28.73%
Briacell Therap N/A -153.53%-129.26%

AquaBounty Technologies has higher revenue and earnings than Briacell Therap. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AquaBounty Technologies$2.47M2.66-$18.49M-$0.82N/A
Briacell TherapN/AN/A-$26.31M-$7.92N/A

8.9% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by insiders. Comparatively, 0.7% of Briacell Therap shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AquaBounty Technologies has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

In the previous week, AquaBounty Technologies and AquaBounty Technologies both had 2 articles in the media. Briacell Therap's average media sentiment score of 0.82 beat AquaBounty Technologies' score of 0.43 indicating that Briacell Therap is being referred to more favorably in the news media.

Company Overall Sentiment
AquaBounty Technologies Neutral
Briacell Therap Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AquaBounty Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Briacell Therap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

AquaBounty Technologies beats Briacell Therap on 7 of the 10 factors compared between the two stocks.

How does AquaBounty Technologies compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Genenta Science has higher earnings, but lower revenue than AquaBounty Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genenta ScienceN/AN/A-$7.39MN/AN/A
AquaBounty Technologies$2.47M2.66-$18.49M-$0.82N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
AquaBounty Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Comparatively, 1.0% of AquaBounty Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Genenta Science and Genenta Science both had 2 articles in the media. Genenta Science's average media sentiment score of 0.94 beat AquaBounty Technologies' score of 0.43 indicating that Genenta Science is being referred to more favorably in the media.

Company Overall Sentiment
Genenta Science Positive
AquaBounty Technologies Neutral

Genenta Science has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

Genenta Science's return on equity of 0.00% beat AquaBounty Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Genenta ScienceN/A N/A N/A
AquaBounty Technologies N/A -147.07%-28.73%

Summary

Genenta Science beats AquaBounty Technologies on 6 of the 8 factors compared between the two stocks.

How does AquaBounty Technologies compare to NextCure?

AquaBounty Technologies (NASDAQ:AQB) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

In the previous week, AquaBounty Technologies had 1 more articles in the media than NextCure. MarketBeat recorded 2 mentions for AquaBounty Technologies and 1 mentions for NextCure. NextCure's average media sentiment score of 1.87 beat AquaBounty Technologies' score of 0.43 indicating that NextCure is being referred to more favorably in the news media.

Company Overall Sentiment
AquaBounty Technologies Neutral
NextCure Very Positive

AquaBounty Technologies has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, NextCure has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

8.9% of AquaBounty Technologies shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 1.0% of AquaBounty Technologies shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AquaBounty Technologies has higher revenue and earnings than NextCure. AquaBounty Technologies is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AquaBounty Technologies$2.47M2.66-$18.49M-$0.82N/A
NextCureN/AN/A-$55.84M-$8.70N/A

AquaBounty Technologies' return on equity of -147.07% beat NextCure's return on equity.

Company Net Margins Return on Equity Return on Assets
AquaBounty TechnologiesN/A -147.07% -28.73%
NextCure N/A -154.62%-100.19%

NextCure has a consensus price target of $19.00, indicating a potential upside of 197.34%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than AquaBounty Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AquaBounty Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NextCure
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

AquaBounty Technologies and NextCure tied by winning 7 of the 14 factors compared between the two stocks.

How does AquaBounty Technologies compare to Tevogen Bio?

AquaBounty Technologies (NASDAQ:AQB) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, AquaBounty Technologies had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 2 mentions for AquaBounty Technologies and 1 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 1.87 beat AquaBounty Technologies' score of 0.43 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company Overall Sentiment
AquaBounty Technologies Neutral
Tevogen Bio Very Positive

AquaBounty Technologies has higher revenue and earnings than Tevogen Bio. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AquaBounty Technologies$2.47M2.66-$18.49M-$0.82N/A
Tevogen BioN/AN/A-$26.27M-$4.63N/A

Tevogen Bio has a consensus price target of $100.00, indicating a potential upside of 1,332.66%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts clearly believe Tevogen Bio is more favorable than AquaBounty Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AquaBounty Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Tevogen Bio
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Tevogen Bio's return on equity of 0.00% beat AquaBounty Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
AquaBounty TechnologiesN/A -147.07% -28.73%
Tevogen Bio N/A N/A -468.32%

8.9% of AquaBounty Technologies shares are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by company insiders. Comparatively, 65.6% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AquaBounty Technologies has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

Summary

AquaBounty Technologies beats Tevogen Bio on 7 of the 13 factors compared between the two stocks.

How does AquaBounty Technologies compare to Kyntra Bio?

AquaBounty Technologies (NASDAQ:AQB) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, Kyntra Bio had 1 more articles in the media than AquaBounty Technologies. MarketBeat recorded 3 mentions for Kyntra Bio and 2 mentions for AquaBounty Technologies. Kyntra Bio's average media sentiment score of 0.63 beat AquaBounty Technologies' score of 0.43 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company Overall Sentiment
AquaBounty Technologies Neutral
Kyntra Bio Positive

Kyntra Bio has a consensus target price of $32.50, indicating a potential upside of 317.74%. Given Kyntra Bio's stronger consensus rating and higher possible upside, analysts plainly believe Kyntra Bio is more favorable than AquaBounty Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AquaBounty Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Kyntra Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

Kyntra Bio has higher revenue and earnings than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AquaBounty Technologies$2.47M2.66-$18.49M-$0.82N/A
Kyntra Bio$6.44M4.89$183.45M$45.300.17

Kyntra Bio has a net margin of 2,199.13% compared to AquaBounty Technologies' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat AquaBounty Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
AquaBounty TechnologiesN/A -147.07% -28.73%
Kyntra Bio 2,199.13%N/A -47.27%

AquaBounty Technologies has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market.

8.9% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Kyntra Bio beats AquaBounty Technologies on 15 of the 17 factors compared between the two stocks.

Get AquaBounty Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for AQB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AQB vs. The Competition

Export
MetricAquaBounty TechnologiesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$6.57M$3.92B$7.12B$12.85B
Dividend YieldN/A3.61%2.54%11.27%
P/E Ratio-1.5511.69272.8925.51
Price / Sales2.661,396.47686.41123.12
Price / CashN/A44.0628.7436.03
Price / Book-2.6016.8111.066.34
Net Income-$18.49M-$22.71M$3.47B$349.45M
7 Day Performance-2.67%2.88%1.27%-0.10%
1 Month Performance40.79%13.05%8.28%4.36%
1 Year Performance8.05%55.07%24.29%14.91%

AquaBounty Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AQB
AquaBounty Technologies
0.3599 of 5 stars		$1.28
+2.0%		N/A+5.9%$6.57M$2.47MN/A100
BCTX
Briacell Therap
0.6948 of 5 stars		$3.53
+4.1%		N/A-52.0%$29.93MN/AN/A8
GNTA
Genenta Science
0.8577 of 5 stars		$1.17
-7.1%		N/A-74.5%$29.73MN/AN/A7
NXTC
NextCure
3.884 of 5 stars		$6.65
-13.7%		$19.00
+185.7%		+21.1%$29.66MN/AN/A90
TVGN
Tevogen Bio
2.4433 of 5 stars		$6.31
-4.1%		$100.00
+1,484.8%		-84.9%$28.99MN/AN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AQB) was last updated on 8/31/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel